Emergent BioSolutions (NYSE:EBS) Shares Gap Up After Analyst Upgrade

Emergent BioSolutions Inc. (NYSE:EBS) shares gapped up prior to trading on Thursday after Benchmark raised their price target on the stock from $8.00 to $12.00. The stock had previously closed at $9.20, but opened at $11.43. Benchmark currently has a buy rating on the stock. Emergent BioSolutions shares last traded at $12.32, with a volume of 1,642,442 shares trading hands.

Separately, Rodman & Renshaw reissued a “buy” rating and set a $16.00 price objective on shares of Emergent BioSolutions in a research note on Friday, September 13th.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds have recently made changes to their positions in the business. Avidian Wealth Solutions LLC purchased a new position in Emergent BioSolutions in the first quarter valued at about $33,000. CWM LLC boosted its holdings in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock worth $34,000 after acquiring an additional 4,906 shares during the period. Tidal Investments LLC purchased a new stake in shares of Emergent BioSolutions during the first quarter valued at approximately $34,000. Meeder Asset Management Inc. purchased a new stake in shares of Emergent BioSolutions during the second quarter valued at approximately $41,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Emergent BioSolutions during the first quarter worth $57,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

Emergent BioSolutions Stock Up 27.4 %

The firm’s 50 day moving average price is $8.32 and its two-hundred day moving average price is $7.65. The firm has a market capitalization of $620.11 million, a PE ratio of -1.09 and a beta of 1.57. The company has a quick ratio of 0.54, a current ratio of 1.06 and a debt-to-equity ratio of 1.16.

Emergent BioSolutions (NYSE:EBS) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($2.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($1.35). Emergent BioSolutions had a negative net margin of 53.26% and a negative return on equity of 34.38%. The firm had revenue of $254.70 million during the quarter, compared to analysts’ expectations of $199.47 million. During the same period in the previous year, the company earned ($1.06) earnings per share. As a group, research analysts forecast that Emergent BioSolutions Inc. will post -1.3 EPS for the current fiscal year.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.